These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 24388965)

  • 41. A Chikungunya Virus
    Bartholomeeusen K; Utt A; Coppens S; Rausalu K; Vereecken K; Ariën KK; Merits A
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29695432
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.
    Delang L; Segura Guerrero N; Tas A; Quérat G; Pastorino B; Froeyen M; Dallmeier K; Jochmans D; Herdewijn P; Bello F; Snijder EJ; de Lamballerie X; Martina B; Neyts J; van Hemert MJ; Leyssen P
    J Antimicrob Chemother; 2014 Oct; 69(10):2770-84. PubMed ID: 24951535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structural characterization and biological function of bivalent binding of CD2AP to intrinsically disordered domain of chikungunya virus nsP3 protein.
    Agback P; Dominguez F; Pustovalova Y; Lukash T; Shiliaev N; Orekhov VY; Frolov I; Agback T; Frolova EI
    Virology; 2019 Nov; 537():130-142. PubMed ID: 31493651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conserved motifs in the hypervariable domain of chikungunya virus nsP3 required for transmission by Aedes aegypti mosquitoes.
    Göertz GP; Lingemann M; Geertsema C; Abma-Henkens MHC; Vogels CBF; Koenraadt CJM; van Oers MM; Pijlman GP
    PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006958. PubMed ID: 30412583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of a novel antiviral agent targeting the nonstructural protein 4 (nsP4) of chikungunya virus.
    Wada Y; Orba Y; Sasaki M; Kobayashi S; Carr MJ; Nobori H; Sato A; Hall WW; Sawa H
    Virology; 2017 May; 505():102-112. PubMed ID: 28236746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting cap-dependent translation to inhibit Chikungunya virus replication: selectivity of p38 MAPK inhibitors to virus-infected cells due to autophagy-mediated down regulation of phospho-ERK.
    Mudaliar P; Pradeep P; Abraham R; Sreekumar E
    J Gen Virol; 2021 Jul; 102(7):. PubMed ID: 34328830
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple roles of the non-structural protein 3 (nsP3) alphavirus unique domain (AUD) during Chikungunya virus genome replication and transcription.
    Gao Y; Goonawardane N; Ward J; Tuplin A; Harris M
    PLoS Pathog; 2019 Jan; 15(1):e1007239. PubMed ID: 30668592
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Residue 82 of the Chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice.
    Ashbrook AW; Burrack KS; Silva LA; Montgomery SA; Heise MT; Morrison TE; Dermody TS
    J Virol; 2014 Nov; 88(21):12180-92. PubMed ID: 25142598
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A mouse model of chikungunya virus with utility in antiviral studies.
    Dagley A; Julander JG
    Methods Mol Biol; 2013; 1030():439-48. PubMed ID: 23821287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Micafungin is a novel anti-viral agent of chikungunya virus through multiple mechanisms.
    Ho YJ; Liu FC; Yeh CT; Yang CM; Lin CC; Lin TY; Hsieh PS; Hu MK; Gong Z; Lu JW
    Antiviral Res; 2018 Nov; 159():134-142. PubMed ID: 30300716
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity.
    Messaoudi I; Vomaske J; Totonchy T; Kreklywich CN; Haberthur K; Springgay L; Brien JD; Diamond MS; Defilippis VR; Streblow DN
    PLoS Negl Trop Dis; 2013; 7(7):e2343. PubMed ID: 23936572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization.
    Silva LA; Khomandiak S; Ashbrook AW; Weller R; Heise MT; Morrison TE; Dermody TS
    J Virol; 2014 Mar; 88(5):2385-97. PubMed ID: 24371059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lack of nsP2-specific nuclear functions attenuates chikungunya virus replication both in vitro and in vivo.
    Meshram CD; Lukash T; Phillips AT; Akhrymuk I; Frolova EI; Frolov I
    Virology; 2019 Aug; 534():14-24. PubMed ID: 31163352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insights into the role of the cobalt(III)-thiosemicarbazone complex as a potential inhibitor of the Chikungunya virus nsP4.
    Martins DOS; Souza RAC; Freire MCLC; de Moraes Roso Mesquita NC; Santos IA; de Oliveira DM; Junior NN; de Paiva REF; Harris M; Oliveira CG; Oliva G; Jardim ACG
    J Biol Inorg Chem; 2023 Feb; 28(1):101-115. PubMed ID: 36484824
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FHL1 is a key player of chikungunya virus tropism and pathogenesis.
    Meertens L; Hafirassou ML; Couderc T; Bonnet-Madin L; Kril V; Kümmerer BM; Labeau A; Brugier A; Simon-Loriere E; Burlaud-Gaillard J; Doyen C; Pezzi L; Goupil T; Rafasse S; Vidalain PO; Legout AB; Gueneau L; Juntas-Morales R; Yaou RB; Bonne G; de Lamballerie X; Benkirane M; Roingeard P; Delaugerre C; Lecuit M; Amara A
    C R Biol; 2021 Apr; 343(4):79-89. PubMed ID: 33988325
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Radicicol Inhibits Chikungunya Virus Replication by Targeting Nonstructural Protein 2.
    Nam S; Ga YJ; Lee JY; Hwang WY; Jung E; Shin JS; Chen W; Choi G; Zhou B; Yeh JY; Go YY
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0013521. PubMed ID: 33903104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus.
    Bassetto M; De Burghgraeve T; Delang L; Massarotti A; Coluccia A; Zonta N; Gatti V; Colombano G; Sorba G; Silvestri R; Tron GC; Neyts J; Leyssen P; Brancale A
    Antiviral Res; 2013 Apr; 98(1):12-8. PubMed ID: 23380636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chikungunya virus: an update on antiviral development and challenges.
    Kaur P; Chu JJ
    Drug Discov Today; 2013 Oct; 18(19-20):969-83. PubMed ID: 23684571
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fatty acid synthase and stearoyl-CoA desaturase-1 are conserved druggable cofactors of Old World Alphavirus genome replication.
    Bakhache W; Neyret A; McKellar J; Clop C; Bernard E; Weger-Lucarelli J; Briant L
    Antiviral Res; 2019 Dec; 172():104642. PubMed ID: 31678479
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of Chikungunya virus early replication by intracellular nanoantibodies targeting nsP2 Epitope Rich Region.
    Deng Q; Guo Z; Hu H; Li Q; Zhang Y; Wang J; Liao C; Guo C; Li X; Chen Z; Lu J
    Antiviral Res; 2022 Dec; 208():105446. PubMed ID: 36270543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.